All articles tagged with #diabetic macular edema
Kodiak Sciences Inc has decided to discontinue the development of its experimental drug, tarcocimab tedromer, for the treatment of diabetic macular edema. The decision was made after the drug failed to meet its main goal in two late-stage studies and was found to cause an increase in cataracts over time in patients. As a result, the company's shares tumbled 40% in premarket trading.
The FDA rejected Regeneron's new 8-mg version of Eylea due to an ongoing review of inspection findings at a third-party filler, dealing a major blow to the company's attempt to expand the use of its eye injection for the treatment of patients with wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. The company had sought to speed up the FDA's review of this application with a priority review voucher, which typically costs about $100 million.